Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: Savant who wrote (425)	6/17/2003 2:23:07 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 631

>> are you following AGI 1067 << Sort of, very loosely. I've followed inflammation/foam cells and their roles in cardiovascular disease since the concept was first floated. I love the concept of using anti-oxidants. But I don't understand why their molecule is of particular interest, and I also don't appreciate the assertion that the first molecule was designed to have an effect on VCAM-1 expression. But the phase II data looked good. Dunno....... the company gives me a Maxim-like feel, but I haven't had enough contact with them to label them that strongly. I punt.